Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $48.1752W HIGH $121.00
Volume
484.17 K
Value Traded
49.44 M
Short % Float
7.67%
+11.74%Week
+13.39%1 Month
+53.52%3 Month
+104.06%6 Month
+14.96%5 Year
+1,002.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.34 B
EPS (TTM)
2.12
P/E Ratio
55.27
Ent. Value
6.29 B
Total Shares
45.50 M
Float Shares
44.64 M
Insiders
1.88%
Institutions
110.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HAE Catalyst Timeline
Dated clinical, regulatory and corporate events for Haemonetics Corporation
Past FDA Catalysts and PDUFA Decisions
How HAE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$54M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 91%
Small Cap(rank 599 of 658)
Percentile Rank
Haemonetics Corporation faces pipeline headwinds (22/100), with $83M risk-adjusted pipeline value, led by SOLX in Blood Donors (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLX Small moleculeCompletedNCT02145507 | Blood Donors | Phase 1 | COMPLETED | 170 | Jan 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every HAE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Basil Michelle LOfficer (EVP and General Counsel) | Disposition | -2,913 40,405 held | $56.29 | 05/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HAE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 1.4 % (40 %) | 4.16 M | 65.40 K | 40.04% ( 18.70 K) |
HAE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HAE ranks across every disease it competes in
Competitive Position is a premium feature
See how HAE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHAE News
HAENew Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
Haemonetics Corporation announced a new study validating the effectiveness of its VASCADE MVP XL system in large-bore sheath procedures. The retrospective study, involving 1,623 patients, showed rapid hemostasis and a high same-day discharge rate. The FDA recently expanded the system's labeling to include larger sheaths, enhancing its applicability in electrophysiology procedures.
Read more →HAEMartin Madaus Elected to Haemonetics Board of Directors
Haemonetics Corporation has announced the election of Martin Madaus to its Board of Directors, effective July 24, 2026. Dr. Madaus, with over 30 years of experience in diagnostics and life sciences, has held leadership roles in several prominent companies. His extensive background is anticipated to contribute significantly to Haemonetics' strategic goals and operational excellence.
Read more →HAEHaemonetics Updates Financial Reporting Segments
Haemonetics Corporation has announced a new financial reporting segment structure, transitioning from three segments to two. The previous Plasma and Blood Center segments will now be consolidated into the Apheresis segment, while the Hospital segment will be renamed MedSurg. This reorganization is designed to better reflect the company's operational focus and to align disclosures with the new structure. Haemonetics plans to begin reporting results under this new structure with the first quarter of fiscal year 2027, commencing on March 29, 2026.
Read more →HAEHaemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Haemonetics Corporation will have its President and CEO, Chris Simon, participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The event will be available for public viewing through a live webcast, with a replay accessible for 90 days afterward. The company focuses on enhancing healthcare through innovative medical technologies.
Read more →HAEHaemonetics Reports Fourth Quarter and Fiscal 2026 Results Provides Fiscal 2027 Guidance
Haemonetics Corporation reported its fourth quarter and fiscal 2026 financial results, revealing a 4.8% increase in revenue to $346 million. Despite this growth in revenue, the company faced operating losses of $23 million and a decrease in gross margin. The report showed strong performance in its Plasma and Blood Management Technologies, while the acquisition of Vivasure Medical Limited did not impact organic revenue growth. The company provided guidance for fiscal 2027, expecting a reported revenue growth of 4-7%.
Read more →HAENew Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Haemonetics Corporation announced a new study highlighting the VASCADE MVP® XL's efficacy and safety in large-bore venous access closure procedures. The study demonstrated superior performance compared to the VASCADE MVP® system, achieving 0% bleeding complications. The FDA has approved expanded labeling for the VASCADE MVP XL, allowing its use with larger procedural sheaths, enhancing its role in electrophysiology.
Read more →HAEHaemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
Haemonetics Corporation has received FDA approval to expand the labeling of its VASCADE MVP XL venous vascular closure system for use with larger procedural sheaths. This approval is based on the successful AMBULATE EXPAND trial, which demonstrated no complications in patients. The expansion allows for broader application in advanced vascular closure procedures, particularly in pulsed field ablation and left atrial appendage closure.
Read more →HAEHaemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
Haemonetics Corporation has received FDA 510(k) clearance for its NexSys PCS Plasma Collection System featuring Persona PLUS technology. This next-generation system aims to enhance plasma collection efficiency, showing a mid-single digit percent increase in plasma volume per donation based on clinical trial results. The clearance supports the company's commitment to innovation in plasma-derived therapies.
Read more →HAEHaemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
Haemonetics Corporation announced that CEO Chris Simon will participate in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This engagement aims to enhance investor relations and showcase the company's medical technology innovations.
Read more →HAEHaemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation has made its financial results for the third quarter of fiscal 2026 available on its Investor Relations website. The results cover the period ending December 27, 2025. A conference call and webcast are scheduled for February 5, 2026, at 8:00 a.m. ET to discuss these results.
Read more →HAEHaemonetics Reports Third Quarter and Year-to-Date Fiscal 2026 Results Raises Total Company Fiscal 2026 Guidance
Haemonetics Corporation reported its financial results for the third quarter of fiscal 2026, revealing a total revenue of $339 million, which is a 2.7% decline compared to the prior year. Despite this decrease, the company reported growth in adjusted earnings per diluted share and cash flow from operations. The company's CEO expressed confidence in their core businesses, citing blood management technologies and plasma as driving strong performance. They have also raised their fiscal 2026 guidance for adjusted earnings per share and free cash flow.
Read more →HAEHaemonetics Acquires Vivasure Medical Limited
Haemonetics Corporation has acquired Vivasure Medical Limited, a company specializing in percutaneous vessel closure technology. The acquisition includes an upfront payment of €100 million and potential additional payments based on sales growth. Vivasure's PerQseal Elite system offers a sutureless solution for large-bore arteriotomies and venotomies, with promising clinical results. This move aims to strengthen Haemonetics' position in the structural heart and endovascular procedure markets.
Read more →HAEHaemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
Haemonetics Corporation has announced the date for its third quarter fiscal year 2026 financial results, which will be published on February 5, 2026, at 6:00 am ET. Following the release, the company will host a conference call at 8:00 am ET to discuss the results and answer questions. Participants can access the call via teleconference or a live webcast.
Read more →HAEHaemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Haemonetics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference, with CEO Chris Simon scheduled to speak on January 13, 2026. The presentation will be available via a live audio webcast, and a replay will be accessible for 30 days afterward. This event highlights Haemonetics' role in advancing healthcare technology.
Read more →HAE▲ +32.3%on this news
Haemonetics Reports Second Quarter and First Half Fiscal 2026 Results Raises Total Company Fiscal 2026 Guidance
Haemonetics Corporation reported its financial results for the second quarter of fiscal 2026, revealing a 5.3% decline in revenue compared to the prior year. However, the company raised its fiscal guidance and announced improved adjusted earnings per diluted share guidance. Despite challenges in certain segments, specifically the Blood Center, the CEO emphasized the company's strong balance sheet and disciplined execution, which supports growth initiatives and shareholder value. The firm's adjusted operating margin also remained stable.
Read more →About Haemonetics Corporation
Headquarters125 SUMMER STREET, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE PLUS
Trade the next HAE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime